Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Microsoft Corporation stock logo
MSFT
Microsoft
$503.32
+0.4%
$470.64
$344.79
$506.78
$3.73T1.0421.65 million shs16.45 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.65
-0.5%
$23.89
$20.92
$31.54
$146.57B0.5841.79 million shs34.84 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Microsoft Corporation stock logo
MSFT
Microsoft
-0.40%+0.65%+6.49%+29.10%+7.56%
Pfizer Inc. stock logo
PFE
Pfizer
+0.81%+1.27%+6.06%+17.72%-9.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Microsoft Corporation stock logo
MSFT
Microsoft
4.4311 of 5 stars
2.53.03.32.92.82.51.3
Pfizer Inc. stock logo
PFE
Pfizer
4.9685 of 5 stars
3.23.04.24.52.61.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Microsoft Corporation stock logo
MSFT
Microsoft
2.91
Moderate Buy$534.146.12% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.45
Hold$28.5511.31% Upside

Current Analyst Ratings Breakdown

Latest MSFT and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Microsoft Corporation stock logo
MSFT
Microsoft
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$485.00 ➝ $550.00
7/10/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$475.00 ➝ $600.00
7/9/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$600.00
7/2/2025
Microsoft Corporation stock logo
MSFT
Microsoft
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$500.00 ➝ $600.00
6/30/2025
Microsoft Corporation stock logo
MSFT
Microsoft
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingPositive ➝ Positive
6/26/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$482.00 ➝ $530.00
6/25/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$515.00 ➝ $600.00
6/25/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$565.00 ➝ $585.00
6/13/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$515.00 ➝ $565.00
6/11/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$540.00 ➝ $605.00
5/29/2025
Pfizer Inc. stock logo
PFE
Pfizer
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold$28.00 ➝ $25.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Microsoft Corporation stock logo
MSFT
Microsoft
$245.12B15.26$14.91 per share33.76$36.12 per share13.93
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.29$4.34 per share5.91$15.62 per share1.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Microsoft Corporation stock logo
MSFT
Microsoft
$88.14B$12.9438.9034.242.2735.79%32.74%18.13%7/29/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3818.598.470.9412.62%20.33%8.53%8/5/2025 (Estimated)

Latest MSFT and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/AN/AN/A$13.43 billionN/A
7/29/2025Q4 2025
Microsoft Corporation stock logo
MSFT
Microsoft
$3.35N/AN/AN/A$73.79 billionN/A
4/30/2025Q3 2025
Microsoft Corporation stock logo
MSFT
Microsoft
$3.22$3.46+$0.24$3.46$68.54 billion$70.07 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Microsoft Corporation stock logo
MSFT
Microsoft
$3.320.66%N/A25.66%23 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.71%N/A124.64%16 Years

Latest MSFT and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/10/2025
Microsoft Corporation stock logo
MSFT
Microsoft
quarterly$0.830.71%8/21/20258/21/20259/11/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Microsoft Corporation stock logo
MSFT
Microsoft
0.12
1.37
1.36
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96

Institutional Ownership

CompanyInstitutional Ownership
Microsoft Corporation stock logo
MSFT
Microsoft
71.13%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Microsoft Corporation stock logo
MSFT
Microsoft
0.03%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Microsoft Corporation stock logo
MSFT
Microsoft
228,0007.43 billion7.43 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Pfizer (NYSE:PFE) Stock Price Down 1.3% - Here's Why
Croban Purchases New Position in Pfizer Inc. (NYSE:PFE)
Bernstein Sticks to Its Hold Rating for Pfizer (PFE)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Microsoft stock logo

Microsoft NASDAQ:MSFT

$503.32 +1.84 (+0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$503.44 +0.12 (+0.02%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

Pfizer stock logo

Pfizer NYSE:PFE

$25.65 -0.13 (-0.50%)
Closing price 03:59 PM Eastern
Extended Trading
$25.66 +0.01 (+0.02%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.